Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology · HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Long-Term Monitoring and Building Your Care Team

At a Glance

Long-term HAM/TSP care combines repeated mobility and neurological assessments with attention to bladder health, daily function, and warning signs. A coordinated team—including neurology, urology, rehabilitation, therapy, and mental health professionals—helps preserve independence.

Managing HAM/TSP is an ongoing process. Because the condition is chronic and evolves over decades, the goal of your medical team is to provide long-term survivorship care that preserves your independence and quality of life for as long as possible [1][2].

This requires a proactive approach to monitoring and a dedicated team of specialists who understand the unique challenges of this rare disease.

Tracking Your Progression

Your doctor will not rely on your memory alone to determine if your condition is changing. Instead, clinics use repeated, standardized clinical examinations combined with your reports of daily function to decide when to adjust your treatment [3].

  • Osame Motor Disability Score (OMDS): This is a common tool for tracking mobility in HAM/TSP. It measures your level of walking independence on a scale from 0 to 13. While studies track average changes in large groups, your individual trajectory is highly variable and unique to you [4][5].
  • Timed 10-Meter Walk: A functional test where you are timed walking a short distance [6][7]. Keep in mind that walk times can fluctuate based on daily fatigue, pain, footwear, or whether you are using an assistive device, so a single slow time does not automatically mean the disease has progressed.
  • Expanded Disability Status Scale (EDSS): Often used in multiple sclerosis, this scale helps your doctor assess your overall neurological health across several different systems, such as balance, bowel, and sensation [8].

The Role of Biomarkers

While physical exams are the clinical gold standard, some specialized centers or clinical trials track biomarkers—biological signs in your blood or spinal fluid—to assess inflammation [9].

Proteins like CXCL10 and neopterin in the Cerebrospinal Fluid (CSF) are sometimes measured in research to see if the immune system is actively attacking the spinal cord [10][9]. Doctors may also track your proviral load (the amount of virus in your blood cells), though it often reaches a stable “plateau” in many patients and doesn’t always predict your day-to-day symptoms [11]. It is important to note that serial spinal taps and biomarker testing are not routine for every patient, and these research tools are just one piece of the puzzle alongside your actual physical function.

Building Your Multidisciplinary Team

Because HAM/TSP affects many different parts of your life, a single doctor is rarely enough. A comprehensive care team should ideally include:

  • Neurologist/Neuroimmunologist: The lead “architect” of your care who manages disease-modifying therapies and tracks neurological progression [3].
  • Urologist: Essential for managing bladder symptoms and ensuring your kidneys remain healthy, often utilizing specialized testing like urodynamics [12].
  • Physiatrist (Rehab Doctor): A specialist in physical medicine who can coordinate your mobility aids, bracing, and long-term exercise goals [2].
  • Physical and Occupational Therapists: To help you maintain strength, improve balance, and adapt your daily activities and home for safety [13][14].
  • Mental Health Professional: Chronic illness brings significant emotional weight; psychosocial support, counseling, and connecting with peer support groups are standard parts of holistic care [15].

Staying Vigilant

Part of long-term monitoring is knowing when to raise the alarm. While HAM/TSP usually moves slowly, your team will continue to monitor your overall health, including screening for other issues.

You should notify your team immediately if you experience rapid loss of walking ability, new lumps (swollen lymph nodes), unexplained fevers, new weakness in your arms, or a significant change in your blood counts [16][17]. Reassessing these symptoms ensures that your care plan always matches your current health status and safely addresses any new complications.

Common questions in this guide

How do doctors monitor whether HAM/TSP is progressing?
Doctors compare repeated neurological examinations and reports of daily function over time. They may use the Osame Motor Disability Score, a timed 10-meter walk, or the Expanded Disability Status Scale to assess mobility and other nervous-system functions. One slow walk or one difficult day does not necessarily mean the disease has progressed.
What does the Osame Motor Disability Score measure?
The Osame Motor Disability Score measures how independently a person can walk on a scale from 0 to 13. It helps clinicians compare mobility at different visits, but each person’s pattern of change can be different.
Are CXCL10, neopterin, and proviral load tests routine for HAM/TSP?
These measurements may be used by specialized centers or in clinical research to study inflammation and the amount of HTLV-1 in blood cells. Spinal-fluid testing and repeated biomarker testing are not routine for every person with HAM/TSP, and results do not always predict day-to-day symptoms.
Which specialists can help manage HAM/TSP over the long term?
A long-term team may include a neurologist or neuroimmunologist, urologist, rehabilitation physician, physical therapist, occupational therapist, and mental health professional. Working together can address movement, bladder health, daily activities, emotional well-being, and independence.
What HAM/TSP symptoms require an urgent call to the medical team?
Contact the medical team promptly for rapid loss of walking ability, new weakness in the arms, swollen lymph nodes, unexplained fever, or a significant change in blood counts. These changes may need evaluation rather than waiting for a routine appointment.
How can I prepare for my next HAM/TSP appointment?
Keep a record of walking distance, falls, bladder symptoms, and other changes in daily function. Sharing this information with the care team can make it easier to identify trends and decide whether monitoring or treatment should change.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with HTLV-1 or HAM/TSP do you currently care for in your practice?
  2. 2.Which specific scale or functional tests will you use to track my mobility, and how often will we repeat them?
  3. 3.What is the protocol for involving a urologist or a physical therapist in my long-term care?
  4. 4.What symptoms should trigger an immediate call to your office versus waiting for our next scheduled visit?
  5. 5.Under what circumstances would you recommend repeating lab work or checking inflammatory markers?
  6. 6.How does your team screen for other HTLV-1 complications, and how frequently is that done?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: The impact of a neglected disease on the quality of life.

    Rosadas C, Assone T, Yamashita M, et al.

    PLoS neglected tropical diseases 2020; (14(10)):e0008761 doi:10.1371/journal.pntd.0008761.

    PMID: 33064742
  2. 2

    Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions - A Narrative Review.

    Rezaei MM, Nia MK, Rouzbahani KA, et al.

    Health science reports 2026; (9(8)):e72863 doi:10.1002/hsr2.72863.

    PMID: 42534713
  3. 3

    Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy.

    Mashkani B, Jalili Nik M, Rezaee SA, Boostani R

    Expert review of neurotherapeutics 2023; (23(12)):1233-1248 doi:10.1080/14737175.2023.2272639.

    PMID: 37933802
  4. 4

    Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.

    Tsutsumi S, Sato T, Yagishita N, et al.

    Orphanet journal of rare diseases 2019; (14(1)):227 doi:10.1186/s13023-019-1212-4.

    PMID: 31639014
  5. 5

    Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net).

    Coler-Reilly AL, Yagishita N, Suzuki H, et al.

    Orphanet journal of rare diseases 2016; (11(1)):69 doi:10.1186/s13023-016-0451-x.

    PMID: 27225443
  6. 6

    Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.

    Sato T, Nagai M, Watanabe O, et al.

    Journal of neurology 2024; (271(6)):3471-3485 doi:10.1007/s00415-024-12239-x.

    PMID: 38430272
  7. 7

    Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.

    Sato T, Yamauchi J, Yagishita N, et al.

    Brain : a journal of neurology 2023; (146(8)):3181-3191 doi:10.1093/brain/awad139.

    PMID: 37093965
  8. 8

    Early-Onset HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

    Schwalb A, Pérez-Muto V, Cachay R, et al.

    Pathogens (Basel, Switzerland) 2020; (9(6)) doi:10.3390/pathogens9060450.

    PMID: 32517313
  9. 9

    Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.

    Souza FDS, Freitas NL, Gomes YCP, et al.

    Frontiers in immunology 2021; (12()):737941 doi:10.3389/fimmu.2021.737941.

    PMID: 34764955
  10. 10

    Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1-Associated Myelopathy and Correlates With Neuroinflammation.

    Rosadas C, Zetterberg H, Heslegrave A, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2021; (8(6)) doi:10.1212/NXI.0000000000001090.

    PMID: 34611039
  11. 11

    Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?

    Martins ML, Guimarães JC, Ribas JG, et al.

    Journal of neurovirology 2017; (23(1)):125-133 doi:10.1007/s13365-016-0484-x.

    PMID: 27678093
  12. 12

    Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T-cell leukemia virus type I-associated myelopathy/tropical spastic paraparesis.

    Kumekawa T, Akaihata H, Natsuya H, et al.

    IJU case reports 2024; (7(6)):438-441 doi:10.1002/iju5.12773.

    PMID: 39498183
  13. 13

    Pilates exercise improves the clinical and immunological profiles of patients with human T-cell lymphotropic virus 1 associated myelopathy: A pilot study.

    Klautau AV, da Silva Pinto D, Santana BB, et al.

    Journal of bodywork and movement therapies 2020; (24(3)):1-8 doi:10.1016/j.jbmt.2020.02.012.

    PMID: 32825975
  14. 14

    Balance Impairments in Patients with Human T-Cell Lymphotropic Virus Type 1 Infection.

    Vasconcelos BHB, Callegari B, Costa KHA, et al.

    Scientific reports 2019; (9(1)):11456 doi:10.1038/s41598-019-47920-z.

    PMID: 31391511
  15. 15

    Lived Experience of Human T-cell Leukemia Virus type-1 -Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A Phenomenology Study.

    Davoudi M, Boostani R, Manzari ZS

    Iranian journal of medical sciences 2024; (49(5)):294-301 doi:10.30476/IJMS.2023.97867.2973.

    PMID: 38751877
  16. 16

    A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma: A case report and review of the literature.

    Tamaki K, Mera H, Takeshita S, et al.

    Medicine 2021; (100(40)):e27450 doi:10.1097/MD.0000000000027450.

    PMID: 34622865
  17. 17

    Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient.

    Takeda R, Ishigaki T, Ohno N, et al.

    International journal of hematology 2020; (111(6)):891-896 doi:10.1007/s12185-019-02815-7.

    PMID: 31930455

This page is for informational purposes only and does not constitute medical advice about HAM/TSP. Your neurologist and care team can recommend the monitoring schedule, specialists, and urgent symptoms appropriate for you.

Get notified when new evidence is published on Tropical spastic paraparesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.